TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02161796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT01001338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA594
Description: Uricosuric agent for the treatment of gout.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol
Study: NCT05052034

Intervention type: OTHER
Intervention: Music
Description: Through headphones, the patients would listen to different types of music during the intervention.

Intervention type: OTHER
Intervention: Music
Description: Through headphones, the patients would listen to different types of music during the intervention.
Study: NCT01001338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol
Study: NCT01940068

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid based formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid based formula
Study: NCT01237275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI treated group
Description: characterize in arm of a study (SSRI treated group)
Study: NCT00903006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0646
Description: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0646
Description: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
Study: NCT03287921

Intervention type: DRUG
Intervention: mono bronchodilatation
Description: within indication according to current GOLD recommendation

Intervention type: DRUG
Intervention: mono bronchodilatation
Description: within indication according to current GOLD recommendation

Intervention type: DRUG
Intervention: dual bronchodilatation
Description: within indication according to current GOLD recommendation

Intervention type: DRUG
Intervention: dual bronchodilatation
Description: within indication according to current GOLD recommendation
Study: NCT00857285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: olmesartan medoxomil oral tablets, once daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: losartan oral tablets, once daily for up to 12 weeks
Study: NCT00903006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
Study: NCT02890212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium supplementation
Description: administration of selenium pills (400 micrograms) for randomized subjects

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of placebo pills for randomized subjects
Study: NCT01253109

Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device for continuous IOP monitoring
Study: NCT03203031

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Standard general anesthesia
Study: NCT03572179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3d printed positioning tray
Description: 3d printed positioning tray for lingual fixed retainer placement in treatment group
Study: NCT00644358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: titration to 40 milligrams (mg) every day (qd) for 1 year
Study: NCT03180385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally-Adusted Ventilatory Assist (NAVA)
Description: Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Positive Airway Pressure Support (BiPAP)
Description: Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
Study: NCT01774201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises with positive expiratory pressure.
Study: NCT03669614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled AR-501
Description: single and multiple ascending doses of inhaled AR-501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: single and multiple ascending doses of inhaled placebo
Study: NCT01406301

Intervention type: DRUG
Intervention: fondaparinux
Description: fondaparinux
Study: NCT03203031

Intervention type: PROCEDURE
Intervention: Quadratus lumborum block
Description: Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
Study: NCT00666601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-700 (active moiety)
Description: A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 (pro-drug)
Description: Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
Study: NCT00574756

Intervention type: DRUG
Group type: OTHER
Intervention: ranolazine
Description: extended release 500 mg twice a day for two weeks

Intervention type: DRUG
Group type: OTHER
Intervention: ranolazine
Description: extended release 500 mg twice a day for two weeks
Study: NCT03735836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAG-EPA/MAG-DHA omega-3 oils
Description: The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAG-EPA/MAG-DHA omega-3 oils
Description: The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
Study: NCT01774032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
Study: NCT00627588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProSavin
Description: ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ProSavin
Description: ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
Study: NCT01611792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise protocol
Description: The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength and conditioning exercise protocol
Description: This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
Study: NCT01759420

Intervention type: DRUG
Intervention: Ondansetron
Description: 4mg of intravenous ondansetron
Study: NCT02261259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Up to 4 sessions of osteopathic manipulative treatment (once per week)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Up to 4 sessions of osteopathic manipulative treatment (once per week)
Study: NCT00735631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SISO model-based predictive closed-loop system
Description: The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
Study: NCT02878577

Intervention type: DEVICE
Intervention: fMRI
Description: fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).

Intervention type: DEVICE
Intervention: fMRI
Description: fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
Study: NCT02010268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of stool samples
Description: A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
Study: NCT04284215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel combined with cisplatin
Description: Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
Study: NCT04842708

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaccination against COVID19
Description: subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
Study: NCT02949349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Daily dose not more than 10mg, orally, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Daily dose not more than 10mg, orally, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Daily dose not more than 10mg, orally, for 24 weeks.
Study: NCT01819155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal trivalent inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline (bacteriostatic 0.9% sodium chloride for injection)
Study: NCT00128895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: azathioprine 2 mg/kg oral once daily, duration according to arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Description: azathioprine 2 mg/kg oral once daily, duration according to arm
Study: NCT01780116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence therapy
Description: Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
Study: NCT00421057

Intervention type: BEHAVIORAL
Intervention: Combined Strength Training and Functional Endurance Exercise
Description: Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking approximately 30 minutes total to complete.
Study: NCT00506870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INRatio / Coaguchek XS
Description: INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Conventional follow-up of anti-coagulation
Description: At least, one follow-up of INR per month. Measured in laboratory.
Study: NCT00394199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/Formoterol Fumarate 100/10
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100
Description: Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate 10
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT02960386

Intervention type: OTHER
Group type: OTHER
Intervention: Machine Learning Algorithm
Description: The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
Study: NCT01796717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C Group
Description: Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E Group
Description: Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
Study: NCT02602886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention Therapy
Description: The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
Study: NCT02724098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study: NCT04284215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin paclitaxel combined with cisplatin
Description: Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
Study: NCT04619940

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: iHandy application
Description: The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iHandy application
Description: The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Goniometer
Description: While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Goniometer
Description: While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
Study: NCT00583193

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine hydrochloride
Description: Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
Study: NCT02608723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard shock waves device
Description: 3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Austere shock waves device
Description: 3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sophisticated shock waves device
Description: 3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
Study: NCT02871531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy